IRIS
DE LUCA, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.088
EU - Europa 19.492
AS - Asia 7.536
SA - Sud America 1.569
AF - Africa 188
OC - Oceania 46
Continente sconosciuto - Info sul continente non disponibili 19
Totale 52.938
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.867
GB - Regno Unito 5.880
RU - Federazione Russa 2.969
CN - Cina 2.910
IT - Italia 2.673
IE - Irlanda 2.470
SG - Singapore 2.456
UA - Ucraina 1.872
BR - Brasile 1.373
DE - Germania 924
FR - Francia 888
SE - Svezia 874
HK - Hong Kong 796
VN - Vietnam 440
FI - Finlandia 417
KR - Corea 203
IN - India 146
CA - Canada 126
ES - Italia 103
TR - Turchia 101
NL - Olanda 95
BD - Bangladesh 81
AR - Argentina 71
ZA - Sudafrica 69
AT - Austria 66
BE - Belgio 60
MX - Messico 58
IQ - Iraq 50
PL - Polonia 49
IR - Iran 43
PK - Pakistan 40
JP - Giappone 36
AU - Australia 35
ID - Indonesia 32
CO - Colombia 29
VE - Venezuela 29
CZ - Repubblica Ceca 26
EC - Ecuador 25
SA - Arabia Saudita 24
MA - Marocco 20
UZ - Uzbekistan 20
EU - Europa 16
PH - Filippine 16
AE - Emirati Arabi Uniti 15
GR - Grecia 15
KE - Kenya 15
IL - Israele 14
EG - Egitto 13
LT - Lituania 13
PY - Paraguay 13
KZ - Kazakistan 12
PT - Portogallo 12
CI - Costa d'Avorio 11
JO - Giordania 11
NP - Nepal 11
UG - Uganda 11
CH - Svizzera 10
MY - Malesia 10
CL - Cile 9
JM - Giamaica 9
PE - Perù 9
SK - Slovacchia (Repubblica Slovacca) 9
UY - Uruguay 9
BG - Bulgaria 8
DZ - Algeria 8
ET - Etiopia 8
NZ - Nuova Zelanda 7
OM - Oman 7
PA - Panama 7
TN - Tunisia 7
AL - Albania 6
AZ - Azerbaigian 6
HU - Ungheria 6
KG - Kirghizistan 6
LB - Libano 6
LU - Lussemburgo 6
NG - Nigeria 6
PS - Palestinian Territory 6
TH - Thailandia 6
CR - Costa Rica 5
DK - Danimarca 5
EE - Estonia 5
LV - Lettonia 5
NO - Norvegia 5
TW - Taiwan 5
AM - Armenia 4
BA - Bosnia-Erzegovina 4
BH - Bahrain 4
DO - Repubblica Dominicana 4
GH - Ghana 4
LK - Sri Lanka 4
MN - Mongolia 4
RS - Serbia 4
SN - Senegal 4
AO - Angola 3
BS - Bahamas 3
BW - Botswana 3
BY - Bielorussia 3
GA - Gabon 3
HN - Honduras 3
Totale 52.899
Salva come PNG Salva come JPEG
Città #
Southend 5.324
Fairfield 2.920
Dallas 2.639
Dublin 2.453
Chandler 1.802
Ashburn 1.799
Jacksonville 1.537
Woodbridge 1.473
Singapore 1.186
Seattle 1.157
Wilmington 1.143
Cambridge 1.025
Houston 1.013
Hong Kong 776
Moscow 727
Beijing 664
Ann Arbor 649
Santa Clara 619
Menlo Park 510
Munich 496
Princeton 496
Nanjing 459
Siena 423
Boardman 276
Helsinki 271
Dong Ket 229
Los Angeles 220
The Dalles 207
Milan 201
Seoul 198
New York 183
Hefei 180
Rome 180
San Diego 160
Nanchang 146
Shenyang 136
Buffalo 129
Redondo Beach 120
Dearborn 115
São Paulo 115
Columbus 101
Tianjin 98
Changsha 90
Hebei 86
London 82
Ho Chi Minh City 75
Council Bluffs 74
San Mateo 74
Shanghai 74
Jiaxing 67
Florence 63
Málaga 63
Bologna 60
Turin 56
Brussels 53
Nuremberg 53
Kunming 52
Zhengzhou 51
Jinan 50
Hanoi 48
Toronto 48
Norwalk 47
Ningbo 46
Izmir 45
Guangzhou 44
San Francisco 43
Turku 41
Vienna 40
Belo Horizonte 39
Düsseldorf 39
Phoenix 39
Frankfurt am Main 38
Chicago 37
Taizhou 36
Brooklyn 34
Naples 34
Warsaw 34
Lancaster 33
Rio de Janeiro 32
Johannesburg 31
Falls Church 30
Tokyo 30
Montreal 29
Genoa 27
Hangzhou 24
Stockholm 24
Atlanta 23
Brasília 23
Redwood City 22
Catania 20
Chennai 20
Denver 20
Melbourne 20
Baghdad 19
Bari 19
Boston 19
Dhaka 19
Lauterbourg 19
Padova 19
Tashkent 18
Totale 36.950
Salva come PNG Salva come JPEG
Nome #
Utilizzo di dalbavancina nella terapia delle infezioni osteoarticolari 1.225
Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: Implications for the activity of next-line regimens from a longitudinal study in Mozambique 637
Meningoencefalite da Listeria e sindrome di Miller-Fisher: un’inusuale associazione 627
A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen 596
Staphylococcus aureus vaccine preclinical and clinical development: current state of the art 539
"EFFICACY AND SAFETY OF 2-DRUG COMBINATION ANTIRETROVIRAL THERAPY IN CLINICAL PRACTICE: RESULTS FROM A SINGLE CENTER STUDY" 529
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 487
UTILIZZO DI MILTEFOSINA IN PAZIENTE CON LEISHMANIOSI MUCOSA ED INFEZIONE DA HIV 428
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study 380
AIDS-associated cerebral toxoplasmosis: an update on diagnosis and treatment. 358
Listeria meningoencephalitis and anti-GQ1b antibody syndrome 332
An outbreak of HIV-1 subtype G among Italian injecting drug users 328
ERITEMA NODOSO RECIDIVANTE E PERSISTENTE REPLICA DI EPSTEIN-BARR VIRUS 323
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe 300
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 287
Non-granulomatous cerebellar infection by Acanthamoeba spp. in an immunocompetent host 279
A novel methodology for large-scale phylogeny partition 278
Paediatric obstructive sleep apnoea syndrome (OSAS) is associated with tonsil colonisation by Streptococcus pyogenes 271
Analisi retrospettiva su infezioni invasive e non invasive da batteri Gram negativi non fermentanti in pazienti ospedalizzati 268
HCMV infection in renal transplant recipients: a retrospective cohort study 261
Clinical and MRI improvement in a case of progressive multifocal leukoencephalopathy 259
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort 259
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 257
Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 256
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 254
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 254
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 253
Virological and Immunological Response to Antiretroviral Regimens Containing Maraviroc in HIV Type 1-Infected Patients in Clinical Practice: Role of Different Tropism Testing Results and of Concomitant Treatments 252
First report of spondylodiscitis due to vancomycin heteroresistant Staphylococcus capitis in immunocompetent host 252
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 252
Case Report: Persistent strongyloidiasis complicated by recurrent meningitis in an HTLV seropositive Peruvian migrant resettled in Italy 250
Impact of transmitted drug resistance in naïve-patients starting 2 NRTI plus a boosted protease-inhibitor (PI) or integrase-inhibitor (INSTI). 249
Nuovi approci diagnostici nelle infezioni pneumococciche: possibile ruolo della Real-time PCR e dei biomarcatori 249
Evolution of macrolide resistance in streptococcus pyogenes over 14 years in an area of central Italy 248
Strategie di vaccinazione anti-pneumococcica nel paziente adulto HIV-positivo: confronto fra vaccino coniugato 13-valente e vaccino polisaccaridico 23-valente 247
Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection 247
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 246
Seroprevalence of hepatitis E virus (HEV) infection in blood donors and renal transplant recipients: a retrospective study from central Italy [Sieroprevalenza dell’infezione da virus dell’epatite E (HEV) in donatori di sangue e pazienti trapiantati di rene: Uno studio retrospettivo dal centro Italia] 242
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 239
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 238
Sieroprevalenza di HEV in donatori di sangue e pazienti trapiantati di rene nella provincia di Siena. 237
Pediatric spinal epidural abscess in an immunocompetent host without risk factors: Case report and review of the literature 236
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score 233
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 232
Un rarissimo caso di infestazione parassitaria cerebellare da Acanthamoeba spp. In soggetto immunocompetente: primo caso in Italia. 228
Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients 222
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 222
Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: a cohort study 218
Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. 217
Un caso di “insolita” spondilodiscite da Staphylococcus capitis 217
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 216
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 216
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals 213
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 213
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 213
FIBRILLO-FLUTTER IN ASSENZA DI SEGNI DI MIOCARDITE IN CORSO DI INFEZIONE DA EBV 209
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study 205
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 200
233. Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. 199
Risposta immunitaria a lungo termine dopo vaccinazione antipneumococcica con vaccino coniugato 13-valente o vaccino polisaccaridico 23-valente in adulti HIV positivi 199
High burden of transmitted HIV-1 drug resistance in Italian patients carrying F1 subtype 198
Prevalence of M75 Streptococcus Pyogenes strains harboring slaa gene in patients affected by pediatric obstructive sleep apnea syndrome in Central Italy 196
A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads 195
PATOGENI COLONIZZANTI IL NASOFARINGE DI SOGGETTI HIV POSITIVI E HIV NEGATIVI 194
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients – evidence from a large observational cohort 194
Evoluzione ed efficace controllo di un vasto focolaio epidemico nosocomiale da Klebsiella pneumoniae produttrice di carbapenemasi in un’area Neurochirurgica: lezioni apprese. 193
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 192
Compartimentalizzazione di HCMV: mancata appropiatezza della sola DNAemia nella diagnosi e nella terapia di una polmonite da HCMV post-trapianto polmonare 191
MIASI CAVITARIA A LOCALIZZAZIONE NASALE DA OESTRUS OVIS: UN CASO CLINICO 190
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. 187
Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: an ARCA cohort study 187
Diagnosi di sarcoidosi in nuova diagnosi di HIV 186
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 186
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project 185
Valutazione della risposta al test IGRA in pazienti pediatrici contatto di TBC o con sospetto clinico di infezione attiva 184
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 182
Gastroenteritis and Intractable Diarrhea in Newborns 181
European guidelines on the clinical management of HIV-1 tropism testing 181
Kaposi Sarcoma Incidence and Survival Among HIV-Infected Homosexual Men After HIV Seroconversion 179
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 179
Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response 178
Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load 176
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 171
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 170
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 170
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 170
Meningite purulenta a decorso atipico in età pediatrica 169
Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy 169
Long-term immune response to 13-valent Pneumococcal Conjugate Vaccine versus 23-valent Polysaccharide Vaccine in HIV-1 infected adults 166
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 165
Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy 165
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 165
Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non-AIDS-Defining Events in a Large Cohort of HIV-Infected Patients 165
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: A multi-cohort study 165
Gestione clinica di effetti collaterali multipli in un paziente con epatite cronica da HCV in trattamento con terapia triplice comprendente telaprevir 163
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 163
LA MALATTIA PNEUMOCOCCICA IN ETÀ PEDIATRICA: CONFRONTO FRA EPOCA PRE- E POST-VACCINALE 163
Phylogenetic analysis provides evidence of interactions between Italian heterosexual and South American homosexual males as the main source of national HIV-1 subtype C epidemics 162
"Buffalo hump" in HIV-1 infection RID G-8810-2011 162
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients 162
Totale 25.180
Salva come PNG Salva come JPEG
Categoria #
all - tutte 164.874
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 164.874
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.631 0 0 0 0 0 639 326 924 318 619 249 556
2021/20223.685 251 482 144 287 141 170 174 188 215 436 354 843
2022/20235.823 377 315 598 902 685 1.288 78 468 630 143 176 163
2023/20243.784 203 123 293 150 153 877 1.228 133 27 127 164 306
2024/20257.828 246 504 619 431 691 451 467 621 788 348 801 1.861
2025/20269.721 1.205 2.259 1.746 1.442 2.901 168 0 0 0 0 0 0
Totale 53.848